iiinova — where your digital self keeps evolving

Edwin C Pratt @theprattlab.bsky.social · 31/10/2025

The Pratt Lab is looking for a postdoctoral associate to build new theranostics! Apply today and please spread the word if you can! Deadline is Nov 13th so act fast! stonybrooku.taleo.net/careersectio...

stonybrooku.taleo.net

Postdoctoral Associate

Click the link provided to see the complete job description.

000

Edwin C Pratt @theprattlab.bsky.social · 24/10/2025

Excited to report the Pratt Lab at Stony Brook in their Cancer Center is open! Keep an eye out for hiring notices! Many thanks to @lewislabmskcc.bsky.social for the mentorship during my years at MSKCC. The lab will be focused on chemogenic combinations with theranostics to treat pancreatic cancer.

010

Reposted by Edwin C Pratt

Freddy E Escorcia, MD/PhD @freddyeescorcia.bsky.social · 22/07/2025

Happy proofs day to those who celebrate… Details forthcoming! #radiopharmaceuticals #theranostics #hcc

171

Edwin C Pratt @theprattlab.bsky.social · 21/07/2025

Excited to share hot off the press our paper outlining a new mesothelin antibody for PET imaging. Many thanks to members of the @lewislabmskcc.bsky.social and Eli Lilly and Co. for making this paper happen! authors.elsevier.com/c/1lTO73SWXP...

authors.elsevier.com

020

Edwin C Pratt @theprattlab.bsky.social · 12/05/2025

Fantastic talk by fellow @paulklauser.bsky.social at iSRS on covalent binding PET tracers! Brilliant work!

020

Edwin C Pratt @theprattlab.bsky.social · 23/01/2025

Out now at Clin Cancer Research we characterized a new Trop-2 antibody for rapid tumor detection in pancreatic, ovarian, and prostate cancers. We also leveraged pretargeting for rapid, high-capacity imaging. Huge thanks to our collaborators for the amazing work! aacrjournals.org/clincancerre...

aacrjournals.org

Pretargeted Trop-2 immunoPET for rapid, selective detection of pancreatic tumors

Abstract. Purpose: Recent clinical advances with the approval of antibody-drug conjugates targeting Trop-2 such as sacituzumab-govitecan and datopotomab-deruxtecan have garnered tremendous interest fo...

011